53 unchanged sentences
Millard, Ph.D.
−Removed: Operating Officer (consultant)
+Added: Operating Officer
Pestano, Ph.D.
118 unchanged sentences
of California-San Francisco.
−Removed: has served as a member of our Board since December 2, 2019.
−Removed: Benton was the President, Chief Executive Officer
−Removed: and Trustee of Pepperdine University from June 2000 to July 2019.
−Removed: Benton was the former chairman of both the American Council of
−Removed: Education, the major coordinating body for all of the nation’s higher education institutions, and the National Association of Independent
−Removed: Colleges and Universities.
−Removed: Benton is also past chair of the Association of Independent California Colleges and Universities and a
−Removed: member of the American Bar Association, the Council for Higher Education Accreditation, the President’s Cabinet of the West Coast
−Removed: Conference, the Association of Presidents of Independent Colleges and Universities, and the Los Angeles World Affairs Council.
−Removed: holds an undergraduate degree in American studies from Oklahoma Christian University and a J.D.
−Removed: from Oklahoma University.
−Removed: Benton’s experience governing academic and other institutions qualifies him to serve on our Board.
Chang serves as Chief Executive Officer of Westlake Realty Group and Chairman of Westlake International Group where he has worked
135 unchanged sentences
business and affairs are managed under the direction of the Board.
−Removed: Our Board consists of eight directors, which are divided into three
−Removed: classes (Class I, II and III) with Class I and III each consisting of three directors and Class II consisting of two directors.
+Added: Our Board consists of seven directors, which are divided into three
+Added: classes (Class I, II and III) with Class I and II each consisting of two directors and Class III consisting of three directors.
standing committees of our Board consist of an audit committee, a compensation committee and a nominating and corporate governance committee.
5 unchanged sentences
have an audit committee consisting of Steve R.
−Removed: Martin, who serves as the chairperson, Bob Gower and Andrew Benton.
−Removed: Each member of the
−Removed: audit committee qualifies as an independent director under the Nasdaq corporate governance standards and the independence requirements
−Removed: of Rule 10A-3 of the Exchange Act.
+Added: Martin, who serves as the chairperson, Bob Gower and Lee Rauch.
+Added: Each member of the audit
+Added: committee qualifies as an independent director under the Nasdaq corporate governance standards and the independence requirements of Rule
+Added: 10A-3 of the Exchange Act.
Our Board has determined that Steve R.
−Removed: Martin qualifies as an “ audit committee financial
−Removed: expert ” as such term is defined in Item 407(d)(5) of Regulation S-K and possesses financial sophistication, as defined under
−Removed: the rules of Nasdaq.
+Added: Martin qualifies as an “ audit committee financial expert ”
+Added: as such term is defined in Item 407(d)(5) of Regulation S-K and possesses financial sophistication, as defined under the rules of Nasdaq.
purpose of the audit committee is to prepare the audit committee report required by the SEC to be included in our proxy statement and
27 unchanged sentences
or waivers of, provisions of our code of ethics on our website.
+Added: Trading Policies and Procedures
+Added: have adopted an Insider Trading Policy governing the purchase, sale, and/or other dispositions of our securities by directors, officers
+Added: and employees, or by the Company itself.
+Added: We believe that this policy is reasonably designed to promote compliance with insider trading
+Added: laws, rules and regulations, and Nasdaq listing standards.
Executive & Director Compensation
13 unchanged sentences
2025 and December 31, 2024.
−Removed: and Principal
+Added: Name and Principal
+Added: Stock and Option
Awards ($) (1)
1 unchanged sentence
Compensation ($) (2)
−Removed: Lynn Kirkpatrick,
+Added: Lynn Kirkpatrick, PhD.
Chief Executive Officer
−Removed: Financial Officer
+Added: Dave Humphrey
+Added: Chief Financial Officer
Geoff Birkett
−Removed: Commercial Officer
+Added: Chief Commercial Officer
accordance with SEC rules, this column reflects the aggregate grant date fair value of the restricted stock awards and stock option
18 unchanged sentences
Humphrey and $353,100 for
−Removed: A five percent (5%) cost of living increase was approved for executive officers, effective March 1, 2025.
Performance-Based Bonuses
15 unchanged sentences
In February 2025, the 2021 Amended and Restated Plan was amended to increase
−Removed: the number of awards that may be granted from 41,139 to 51,626.
+Added: the number of awards authorized from 53,668 to 121,457.
Agreements with our NEOs
93 unchanged sentences
following table provides information regarding outstanding equity awards held by our NEOs as of December 31, 2025.
−Removed: of Securities Underlying Unexercised Options Exercisable (#)
−Removed: of Securities Underlying Unexercised Options Unexercisable (#)
−Removed: Exercise Price ($)
−Removed: Expiration Date
−Removed: of Shares of Stock That Have Not Vested (#)
−Removed: Value of Shares of Stock That Have Not Vested ($)
−Removed: Lynn Kirkpatrick,
+Added: Option Awards
+Added: Number of Securities Underlying Unexercised Options Exercisable (#)
+Added: Number of Securities Underlying Unexercised Options Unexercisable (#)
+Added: Option Exercise Price ($)
+Added: Option Expiration Date
+Added: Number of Shares of Stock That Have Not Vested (#)
+Added: Market Value of Shares of Stock That Have Not Vested ($)
+Added: Lynn Kirkpatrick, PhD.
Dave Humphrey
10 unchanged sentences
our pay-for-performance philosophy, refer to the preceding compensation discussion.
−Removed: following table sets forth specified executive compensation and financial performance measures for our two most recently completed fiscal
−Removed: years, as required under transitional guidance for Smaller Reporting Companies provided by the SEC.
−Removed: We have not paid dividends and do
−Removed: not sponsor any pension arrangements;
+Added: following table sets forth specified executive compensation and financial performance measures for our three most recently completed
+Added: fiscal years, as required under guidance for Smaller Reporting Companies provided by the SEC.
+Added: We have not paid dividends and do not sponsor
+Added: any pension arrangements;
thus, no adjustments are made for these items.
−Removed: Compensation Table Total for PEO (1)
−Removed: Actually Paid to PEO (2)
−Removed: Summary Compensation Table Total for Non-PEO NEOs (3)
−Removed: Compensation Actually Paid to Non-PEO NEOs (4)
−Removed: of Initial Fixed $100 Investment Based on Total Shareholder Return (5)
−Removed: Income (Loss)
+Added: Summary Compensation Table Total for PEO (1)
+Added: Compensation Actually Paid to PEO (2)
+Added: Average Summary Compensation Table Total for Non-PEO NEOs (3)
+Added: Average Compensation Actually Paid to Non-PEO NEOs (4)
+Added: Value of Initial Fixed $100 Investment Based on Total Shareholder Return (5)
+Added: Net Income (Loss)
($ 10,175,700 )
5 unchanged sentences
Grant Date Value of Equity Awards
−Removed: Value as of Year End of Awards Granted in the Year and Outstanding and Unvested as of Year End
−Removed: in Fair Value of Awards Granted in Prior Years and Outstanding and Unvested as of Year End
−Removed: Value as of Vesting Date of Awards Granted and Vested in the Year
−Removed: in Fair Value of Awards Granted in Prior Years that Vested in the Year
+Added: Fair Value as of Year End of Awards Granted in the Year and Outstanding and Unvested as of Year End
+Added: Change in Fair Value of Awards Granted in Prior Years and Outstanding and Unvested as of Year End
+Added: Fair Value as of Vesting Date of Awards Granted and Vested in the Year
+Added: Change in Fair Value of Awards Granted in Prior Years that Vested in the Year
Fair Value as of Prior Year End of Awards Forfeited in the Year
+Added: Total Adjustments
all fiscal years presented, the Non-PEO NEOs were Dave Humphrey and Geoff Birkett.
1 unchanged sentence
Grant Date Value of Equity Awards
−Removed: Value as of Year End of Awards Granted in the Year and Outstanding and Unvested as of Year End
−Removed: in Fair Value of Awards Granted in Prior Years and Outstanding and Unvested as of Year End
−Removed: Value as of Vesting Date of Awards Granted and Vested in the Year
−Removed: in Fair Value of Awards Granted in Prior Years that Vested in the Year
+Added: Fair Value as of Year End of Awards Granted in the Year and Outstanding and Unvested as of Year End
+Added: Change in Fair Value of Awards Granted in Prior Years and Outstanding and Unvested as of Year End
+Added: Fair Value as of Vesting Date of Awards Granted and Vested in the Year
+Added: Change in Fair Value of Awards Granted in Prior Years that Vested in the Year
Fair Value as of Prior Year End of Awards Forfeited in the Year
+Added: Total Adjustments
Shareholder Return is calculated as the sum of (i) the cumulative amount of dividends for the measurement period, assuming reinvestment
5 unchanged sentences
for services rendered to us as of December 31, 2025.
−Removed: Earned or Paid in Cash ($)
+Added: Fees Earned or Paid in Cash ($)
+Added: Option Awards
William Chang
24 unchanged sentences
Ownership Table
−Removed: Name and Address
−Removed: of Beneficial Owners
+Added: Name and Address of Beneficial Owners
+Added: Number of Shares
Officers and Directors
2 unchanged sentences
David Humphrey (3)
+Added: Jeff Millard (4)
Linda Pestano (5)
−Removed: Andrew Benton (5)
William Chang (6)
3 unchanged sentences
Curtis Rosebraugh (11)
−Removed: All directors and named executive officers
−Removed: as a group (eleven individuals)
+Added: All directors and named executive officers as a group (eleven individuals)
Greater than 5% Holders
−Removed: Perceptive Advisors LLC (12)
less than 1%.
3 unchanged sentences
of shares subject to options.
−Removed: 30 shares subject to options.
+Added: of shares subject to options.
2,011 shares subject to options, 209 shares owned directly by Mr.
−Removed: Chang and his wife and 513 shares owned through trusts in which Mr.
+Added: Chang and his wife and 513 shares owned through trusts in which
Chang has sole or shared voting and dispositive power.
The business address for Mr.
−Removed: Chang is 520 El Camino Real, 9th Floor, San Mateo,
+Added: Chang is 520 El Camino Real, 9th Floor, San
+Added: Mateo, CA 94402.
2,013 shares subject to options, 8,126 shares held directly and 33,516 shares that may be acquired through the exercise of (i) warrants
6 unchanged sentences
of shares subject to options.
−Removed: on a Schedule 13G/A filed with the SEC on February 14, 2025, by Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences
−Removed: Master Fund, Ltd., which lists the business address for all parties as 51 Astor Place, 10 th Floor, New York, NY 10003.
Certain Relationships and Related Transactions and Director Independence
59 unchanged sentences
or her background, employment and affiliations, including family relationships, the Board determined that each of Bob Gower, William
−Removed: Chang, Andrew Benton, Steve R.
+Added: Chang, Steve R.
Martin, Adam S.
−Removed: Levin, Lee Rauch and Curtis Rosebraugh is an independent director under the Nasdaq listing
−Removed: rules and Rule 10A-3 of the Exchange Act.
−Removed: In making these determinations, the Board considered the current and prior relationships that
−Removed: each non-employee director has and will have with us and all other facts and circumstances that the Board deems relevant in determining
−Removed: independence, including the beneficial ownership of our common stock by each non- employee director (and related entities) and the transactions
−Removed: involving them described in the section entitled “ Certain Relationships and Related Party Transactions.”
+Added: Levin, Lee Rauch and Curtis Rosebraugh is an independent director under the Nasdaq listing rules and
+Added: Rule 10A-3 of the Exchange Act.
+Added: In making these determinations, the Board considered the current and prior relationships that each non-employee
+Added: director has and will have with us and all other facts and circumstances that the Board deems relevant in determining independence, including
+Added: the beneficial ownership of our common stock by each non- employee director (and related entities) and the transactions involving them
+Added: described in the section entitled “ Certain Relationships and Related Party Transactions.”
Principal Accountant Fees and Services
1 unchanged sentence
public accounting firm to audit our consolidated financial statements beginning with the fiscal year ending December 31, 2023.
+Added: 3, 2025, Moss Adams merged with Baker Tilly US, LLP (“Baker Tilly”) and now operates as Baker Tilly.
following table sets forth the aggregate fees incurred for our independent registered accounting firm for the fiscal years ended December
9 unchanged sentences
of consents in connection with registration statements.
−Removed: The amount for fiscal year 2023 includes $89,250 for the audit of the year ended
−Removed: December 31, 2022, completed in conjunction with the audit of the year ended December 31, 2023.
Audit-related
14 unchanged sentences
Consolidated Statements of Operations for the years ended December 31, 2025 and 2024
−Removed: Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the years ended December 31, 2024 and 2023
+Added: Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2025 and 2024
Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024
4 unchanged sentences
on the Financial Statements
−Removed: have audited the accompanying consolidated balance sheets of Ensysce Biosciences Inc.
−Removed: (the “Company”) as of December 31,
−Removed: 2024 and 2023, the related consolidated statements of operations and comprehensive income (loss), stockholders’ equity (deficit),
−Removed: and cash flows for the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”).
−Removed: In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of
−Removed: the Company as of December 31, 2024 and 2023, and the consolidated results of its operations and its cash flows for the years then ended,
−Removed: in conformity with accounting principles generally accepted in the United States of America.
+Added: We have audited the accompanying consolidated balance sheets of Ensysce
+Added: Biosciences, Inc.
+Added: (the “Company”) as of December 31, 2025 and 2024, the related consolidated statements of operations
+Added: and comprehensive loss, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively
+Added: referred to as the “consolidated financial statements”).
+Added: In our opinion, the consolidated financial statements present fairly,
+Added: in all material respects, the consolidated financial position of the Company as of December 31, 2025 and 2024, and the consolidated
+Added: results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in
+Added: the United States of America.
Concern Uncertainty
−Removed: accompanying financial statements have been prepared assuming that the Company will continue as a going concern.
−Removed: As discussed in Note
−Removed: 2 to the financial statements, the Company has incurred recurring losses from operations and has an accumulated deficit that raise substantial
−Removed: doubt about its ability to continue as a going concern.
+Added: The accompanying consolidated financial statements have been prepared
+Added: assuming that the Company will continue as a going concern.
+Added: As discussed in Note 2 to the consolidated financial statements, the Company
+Added: has suffered recurring losses from operations and has an accumulated deficit.
+Added: These circumstances raise substantial doubt about its ability
+Added: to continue as a going concern.
Management’s plans in regard to these matters are also described in Note 2.
−Removed: The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
−Removed: consolidated financial statements are the responsibility of the Company’s management.
−Removed: Our responsibility is to express an opinion
−Removed: on the Company’s consolidated financial statements based on our audits.
−Removed: We are a public accounting firm registered with the Public
−Removed: Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance
−Removed: with the U.S.
−Removed: federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
−Removed: conducted our audits in accordance with the standards of the PCAOB.
−Removed: Those standards require that we plan and perform the audit to obtain
−Removed: reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
−Removed: The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.
−Removed: of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing
−Removed: an opinion on the effectiveness of the Company’s internal control over financial reporting.
+Added: The consolidated financial
+Added: statements do not include any adjustments that might result from the outcome of this uncertainty.
+Added: These consolidated financial statements are the responsibility of the
+Added: Company’s management.
+Added: Our responsibility is to express an opinion on the Company’s consolidated financial statements based
+Added: on our audits.
+Added: We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”)
+Added: and are required to be independent with respect to the Company in accordance with the U.S.
+Added: federal securities laws and the applicable
+Added: rules and regulations of the Securities and Exchange Commission and the PCAOB.
+Added: We conducted our audits in accordance with the standards of the PCAOB.
+Added: Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements
+Added: are free of material misstatement, whether due to error or fraud.
+Added: The Company is not required to have, nor were we engaged to perform,
+Added: an audit of its internal control over financial reporting.
+Added: As part of our audits, we are required to obtain an understanding of internal
+Added: control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal
+Added: control over financial reporting.
Accordingly, we express no such opinion.
−Removed: audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether
−Removed: due to error or fraud, and performing procedures to respond to those risks.
−Removed: Such procedures included examining, on a test basis, evidence
−Removed: regarding the amounts and disclosures in the consolidated financial statements.
−Removed: Our audits also included evaluating the accounting principles
−Removed: used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.
+Added: Our audits included performing procedures to assess the risks of material
+Added: misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks.
+Added: Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
+Added: Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
+Added: the overall presentation of the consolidated financial statements.
We believe that our audits provide a reasonable basis for our opinion.
Audit Matters
−Removed: audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required
−Removed: to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements
−Removed: and (2) involved our especially challenging, subjective, or complex judgments.
−Removed: We determined that there are no critical audit matters.
−Removed: Moss Adams LLP
+Added: The critical audit matter communicated below is a matter arising from
+Added: the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee
+Added: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially
+Added: challenging, subjective, or complex judgments.
+Added: The communication of critical audit matters does not alter in any way our opinion on the
+Added: consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate
+Added: opinion on the critical audit matter or on the accounts or disclosures to which it relates.
+Added: for Series B Convertible Preferred Stock
+Added: As described in Note 9 to the consolidated financial statements, the Company entered into a Securities Purchase
+Added: Agreement in November 2025 with an institutional investor providing for a registered direct offering and concurrent private placement
+Added: for aggregate financing of $4 million.
+Added: The Securities Purchase Agreement involved the issuance of 4,000 shares of Series B Convertible
+Added: Preferred Stock and 992,000 warrants of which 880,000 warrants were issued to certain institutional investors and 112,000 warrants were
+Added: issued to the placement agent.
+Added: The Company determined both the Series B Convertible Preferred Stock and the warrants were equity-classified.
+Added: Additionally, certain embedded features were identified and assessed to determine whether separate recognition at fair value was required.
+Added: The Company determined that although certain embedded features contained in the Series B Convertible Preferred Stock were required to
+Added: be recognized separately and measured at fair value, presentation as separate derivative liabilities was immaterial.
+Added: determination of fair value of the embedded derivatives involved using complex valuation methodologies and significant assumptions, including
+Added: determining the probability of certain conditions or events occurring.
+Added: We identified the classification of the Series B Convertible Preferred
+Added: Stock and warrants and the classification and valuation of the embedded derivatives as a critical audit matter.
+Added: Auditing the Company’s
+Added: evaluation of certain provisions within the relevant agreements for purposes of the financial statement classification for these financial
+Added: instruments, including the methods and assumptions used to estimate fair value of embedded features, involved especially challenging and
+Added: complex auditor judgment when performing audit procedures and evaluating the results of those procedures.
+Added: Addressing the matter involved performing procedures and evaluating
+Added: audit evidence in connection with forming our overall opinion on the consolidated financial statements.
+Added: Our audit procedures related to
+Added: the evaluation of the financial statement classification of the Series B Convertible Preferred Stock and warrants and the classification
+Added: and valuation of the embedded derivatives included the following, among others:
+Added: ● Obtaining and reviewing the underlying Series B Convertible Preferred Stock agreements to understand the
+Added: terms and conditions, economic substance, and the identification of embedded features.
+Added: ● Utilizing a subject matter expert on technical accounting matters to assist in (i) evaluating relevant
+Added: terms of the agreements in relation to the appropriate accounting literature, and (ii) assessing the appropriateness of conclusions reached
+Added: by the Company.
+Added: ● Obtaining an understanding of management’s process for estimating fair value of the embedded features,
+Added: ○ Evaluating the appropriateness of the method selected;
+Added: ○ Identifying the significant assumptions used to determine fair value and;
+Added: ○ Verifying the application of those assumptions in the method selected.
+Added: ● Testing the data and significant assumptions used to determine fair value of the embedded features, including
+Added: performing procedures to determine whether the data used was complete and accurate and whether management’s estimation of the probability
+Added: of certain conditions or events were reasonable.
+Added: ● Utilizing a valuation specialist to assist in evaluating the reasonableness of the valuation methodology
+Added: and the underlying assumptions.
+Added: Baker Tilly US, LLP
Diego, California
7 unchanged sentences
Total current assets
−Removed: Liabilities and stockholders’ equity (deficit)
+Added: Property and equipment, net
+Added: Liabilities and stockholders’ equity
Current liabilities:
8 unchanged sentences
Commitments and contingencies (Note 7)
−Removed: Stockholders’ equity (deficit)
−Removed: Preferred stock, $ 0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at December 31, 2024 and December 31, 2023
+Added: Stockholders’ equity
+Added: Preferred stock, $ 0.0001 par value, 1,500,000 shares authorized, 4,000 shares issued, 3,305 shares outstanding, and $ 3,635,500 liquidation preference at December 31, 2025;
+Added: no shares issued and outstanding at December 31, 2024
Common stock, $ 0.0001 par value, 250,000,000 shares authorized at December 31, 2025 and December 31, 2024;
6 unchanged sentences
Total Ensysce Biosciences, Inc.
−Removed: stockholders’ equity (deficit)
+Added: stockholders’ equity
Noncontrolling interests in stockholders’ deficit
−Removed: Total stockholders’ equity (deficit)
−Removed: Total liabilities and stockholders’ equity (deficit)
+Added: Total stockholders’ equity
+Added: Total liabilities and stockholders’ equity
accompanying notes are an integral part of these consolidated financial statements.
Biosciences, Inc.
−Removed: Statements of Operations
+Added: Statement of Operations
Year Ended December 31,
8 unchanged sentences
Other income (expense):
−Removed: Loss on conversions and change in fair value of convertible notes
Change in fair value of liability classified warrants
16 unchanged sentences
Biosciences, Inc.
−Removed: Statements of Changes in Stockholders’ Equity (Deficit)
+Added: Statement of Changes in Stockholders’ Equity
+Added: Noncontrolling
Stockholders’ Equity (Deficit)
+Added: Preferred Stock
Noncontrolling
5 unchanged sentences
Settlement of restricted stock units
−Removed: Settlement of commitment fee
Conversion of convertible notes
Public offering
−Removed: Stock-based compensation
−Removed: Issuance of warrants - debt discount
−Removed: Transaction costs associated with public offering
Issuance of common stock upon exercise of warrants
+Added: Issuance of common stock upon warrant inducements
+Added: Transaction costs associated with public offering and warrant inducements
+Added: ( 1,468,131 )
+Added: ( 1,468,131 )
+Added: Stock-based compensation
Reverse split fractional shares
9 unchanged sentences
$ ( 328,483 )
−Removed: $ ( 328,409 )
−Removed: $ ( 651,267 )
−Removed: Settlement of restricted stock units
−Removed: Conversion of convertible notes
Public offering
2 unchanged sentences
Transaction costs associated with public offering and warrant inducements
−Removed: ( 1,468,131 )
−Removed: ( 1,468,131 )
+Added: Issuance of Series B Preferred Stock
+Added: Transaction costs associated with Series B Preferred Stock
+Added: Conversions of preferred stock into common stock
+Added: Consultant compensation
Stock-based compensation
−Removed: Reverse split fractional shares
−Removed: Deemed dividend related to warrants down round provision
( 10,175,700 )
9 unchanged sentences
Biosciences, Inc.
−Removed: Statements of Cash Flow s
+Added: Statement of Cash Flows
Year Ended December 31,
4 unchanged sentences
Accrued interest
−Removed: Amortization of orginal issue discount and debt issuance costs
−Removed: Loss on conversions and change in fair value of convertible notes
+Added: Amortization of original issue discount and debt issuance costs
Change in fair value of liability classified warrants
+Added: Consultant compensation
Stock-based compensation
+Added: Depreciation expense
+Added: Changes in operating assets and liabilities
Unbilled receivable
1 unchanged sentence
Accounts payable
−Removed: ( 1,234,287 )
Accrued expenses and other liabilities
−Removed: ( 1,284,233 )
Net cash used in operating activities
1 unchanged sentence
( 7,502,700 )
+Added: Cash flows from investing activities:
+Added: Investment in property and equipment
+Added: Net cash flows used in investing activities
Cash flows from financing activities:
−Removed: Proceeds from public offerings, net
+Added: Proceeds from public offerings
Proceeds from warrant exercises
Proceeds from warrant inducement, net of issuance costs
−Removed: Transaction costs from public offerings
+Added: Proceeds from issuance of Series B Preferred Stock
Transaction costs associated with public offering and warrant inducements
( 1,468,131 )
−Removed: Proceeds from issuance of convertible notes, net
+Added: Transaction costs associated with Series B Preferred Stock issuance
Repayment of convertible notes
−Removed: ( 1,000,208 )
Repayment of financed insurance premiums
Net cash provided by financing activities
−Removed: Increase (decrease) in cash and cash equivalents
−Removed: ( 2,024,098 )
+Added: Increase in cash and cash equivalents
Cash and cash equivalents beginning of period
1 unchanged sentence
Supplemental cash flow information:
−Removed: Income tax payments
+Added: State minimum tax payments
Supplemental disclosure of non-cash investing and financing activities:
1 unchanged sentence
Incremental fair value of February 2024 Warrant Inducement
+Added: Incremental fair value of April 2025 Warrant Inducement
+Added: Transaction costs under accounts payable and accrued expenses
+Added: Investment in property and equipment under accounts payable
Conversion of convertible notes into common stock
−Removed: Original debt discount from convertible notes
−Removed: Debt discount from warrants issuance
−Removed: Issuance cost from convertible notes
Financed insurance premiums
−Removed: Settlement of commitment fee in shares
Deemed dividend related to warrants down round provision
13 unchanged sentences
Activated Abuse Protection) opioid product candidate, PF614.
−Removed: In addition, the Company is developing its MPAR® (Multi-Pill Abuse Resistant)
+Added: In addition, the Company is developing its MPAR® (Multi-Pill Abuse Resistance)
technology for overdose protection which will be applied to the PF614 program.
15 unchanged sentences
and transactions have been eliminated in the consolidation.
−Removed: March 2023, the Company completed a 1-for-12 reverse split of its outstanding common stock.
December 2024, the Company completed a 1-for-15 reverse split of its outstanding common stock.
22 unchanged sentences
a going concern.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
16 unchanged sentences
Additionally, the Company had a concentration in accounts
−Removed: payable, as three and two research and development vendors made up greater than 10% individually, and 74 % and 38 % in aggregate , of the
−Removed: outstanding accounts payable balance as of December 31, 2024 and 2023, respectively.
+Added: payable, as three research and development vendors made up greater than 10% individually, and 82 % and 74 % in aggregate , of the outstanding
+Added: accounts payable balance as of December 31, 2025 and 2024, respectively.
Company operates and manages its business as one reportable and operating segment.
6 unchanged sentences
and Equipment
−Removed: and equipment are fully depreciated as such there is no depreciation expense recognized in the years ended December 31, 2024 and 2023.
+Added: and equipment are recorded at cost and depreciated using the straight-line method over an estimated useful life of five years .
+Added: December 31, 2025, property and equipment consists of laboratory equipment.
+Added: During the year ended December 31, 2025, the Company recognized
+Added: depreciation expense of $ 6,533 .
+Added: There was no property and equipment as of December 31, 2024 and as such no depreciation expense recognized
+Added: during the year ended December 31, 2024.
Value Measurement
5 unchanged sentences
or a liability.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:
17 unchanged sentences
as of December 31, 2025 and 2024.
−Removed: OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE
−Removed: December 31, 2024
−Removed: Liability classified warrants
+Added: The Company’s Level 3 liabilities as of December 31, 2025, are de minimis.
+Added: SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE
December 31, 2024
Liability classified warrants
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
following table summarizes the change in fair value of the Company’s Level 3 liabilities for the year ended December 31, 2025 (no
level 3 assets as of the year ended December 31, 2025):
−Removed: OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3
+Added: SCHEDULE OF CHANGE IN FAIR VALUE OF LIABILITIES
Liability classified warrants
2 unchanged sentences
Fair value, December 31, 2025
−Removed: September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR
−Removed: abuse deterrent technology for Opioid Use Disorder (the “OUD Grant”).
−Removed: The total approved budget was approximately $ 5.4 million,
−Removed: and the grant period ended August 31, 2024.
−Removed: September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”)
−Removed: awarded the Company a research and development grant related to the development of its MPAR ® overdose prevention technology
−Removed: (the “MPAR Grant”).
−Removed: The initial grant was extended several times and cumulative funding under this grant of approximately
+Added: September 2018, the NIH through NIDA awarded the Company a research and development MPAR Grant.
+Added: The initial grant was extended several
+Added: times and cumulative funding under this grant of approximately $ 10.7
million was completed in December 2023.
−Removed: A new multi-year MPAR Grant was awarded by NIH through NIDA in August 2024, providing total
−Removed: funding of $ 14 million through May 2027.
−Removed: As December 31, 2024, the remaining cash funding under the grant is $ 1.6 million, covering the
−Removed: period through May 31, 2025.
+Added: A new multi-year MPAR
+Added: Grant was awarded by NIH through NIDA in August 2024, providing total funding of $ 15.1
+Added: million through May 2027, as adjusted.
+Added: As of December 31, 2025,
+Added: remaining funding under the grant is $ 7.4
+Added: September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR
+Added: abuse deterrent technology for OUD Grant.
+Added: The total approved budget was approximately $ 5.4 million, and the grant period ended August
Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable.
7 unchanged sentences
revenue recognized under the MPAR Grant and OUD Grant was as follows:
−Removed: OF REVENUE RECOGNITION UNDER GRANTS
+Added: SCHEDULE OF REVENUE RECOGNITION UNDER GRANTS
Year Ended December 31,
3 unchanged sentences
allowances are recorded.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
and Development Costs
40 unchanged sentences
penalties accrued related to unrecognized tax benefits as income tax expense.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the
6 unchanged sentences
for the Convertible Notes for the purposes of the weighted average share calculation below):
−Removed: OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES
+Added: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES
Year Ended December 31,
1 unchanged sentence
Convertible Notes
+Added: Consultant Shares
+Added: Conversions from Series B Preferred Stock
Issued Accounting Pronouncements
−Removed: November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280):
−Removed: Improvements to Reportable Segment Disclosures”,
−Removed: which sets forth improvements to the current segment disclosure requirements in accordance with Topic 280 “Segment Reporting,”
−Removed: including clarifying that entities with a single reportable segment are subject to both new and existing segment reporting requirements.
−Removed: ASU 2023-07 will be effective retrospectively for fiscal years beginning after December 15, 2023, and interim periods beginning after
−Removed: December 15, 2024.
−Removed: The Company adopted the standard with an effective date of January 1, 2024 and the adoption did not have a significant
−Removed: impact on the consolidated financial statements.
December 2023, the FASB issued ASU No.
2023-09, Income Taxes (Topic 740):
−Removed: Improvements to Income Tax Disclosures.” ASU 2023-09
−Removed: requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income
−Removed: ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted.
−Removed: The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
+Added: Improvements to Income Tax Disclosures, which focuses on the
+Added: rate reconciliation and income taxes paid.
+Added: 2023-09 requires public business entities to disclose, on an annual basis, specific
+Added: categories in the effective tax rate reconciliation and provide additional information for reconciling items that meet a quantitative
+Added: In addition, ASU No.
+Added: 2023-09 requires companies to disclose further information about income taxes paid.
+Added: The standard is effective
+Added: for annual periods beginning after December 15, 2024, and may be applied prospectively or retrospectively.
+Added: We adopted the ASU retrospectively
+Added: for the period ending December 31, 2025, and it affects only our disclosures under Note 11, Income taxes, and does not impact our results
+Added: of operations or financial condition.
November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures
10 unchanged sentences
debt instruments should be accounted for as an induced conversion.
−Removed: ASU 2024-04 is effective for all entities after December 15, 2025,
+Added: ASU 2024-04 is effective for all entities for annual reporting periods
+Added: beginning after December 15, 2025, with early adoption permitted.
+Added: The Company is currently evaluating the impact of this guidance on
+Added: its consolidated financial statements.
+Added: December 2025, the FASB issued ASU 2025-10, Government Grants (Topic 832):
+Added: Accounting for Government Grants by Business Entitie s ,
+Added: which set forth new amendments that require entities to recognize government grants when it is probable that the grant conditions will
+Added: be met and the grant will be received, and to provide enhanced disclosures regarding the nature, terms, and financial statement effects
+Added: of such grants.
+Added: The new amendments are effective for public companies with annual reporting periods beginning after December 15, 2028
with early adoption permitted.
The Company is currently evaluating the impact of this guidance on its consolidated financial statements.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS
expenses and other current assets consisted of the following:
−Removed: OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
+Added: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid research and development
3 unchanged sentences
Total prepaid expenses and other current assets
+Added: 5 – OTHER ASSETS
+Added: assets consisted of the following:
+Added: SCHEDULE OF OTHER ASSETS
+Added: Prepaid insurance
+Added: Total other assets
6 – ACCRUED EXPENSES AND OTHER LIABILITIES
2 unchanged sentences
Accrued research and development
+Added: Accrued consultant compensation
Accrued professional fees
22 unchanged sentences
As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
+Added: April 2025, the Company entered into an agreement with a former independent contractor to resolve a dispute over payment.
+Added: denied the allegations but agreed to settle the matter.
+Added: In connection with the settlement agreement, the Company issued 20,000 shares
+Added: of common stock to the consultant in April 2025.
+Added: As of December 31, 2025, the Company accrued a total settlement value of $ 0.2 million.
+Added: January 2025, the Company entered into a product development and supply agreement with Galephar Pharmaceutical Research, Inc., a Puerto
+Added: Rico specialty drug manufacturer (“Galephar”), to support the development, manufacture, packaging and testing of the Company’s
+Added: PF614 and PF614-MPAR drug products for use in clinical trials and potential future commercial launch.
+Added: execution of the agreement, the Company committed to issue 13,801 restricted shares of common stock (representing approximately 1 % of
+Added: the Company’s outstanding common stock), subject to vesting in three tranches upon the achievement of specific operational and
+Added: regulatory milestones.
+Added: The Company accounts for this share grant as nonemployee share-based compensation in accordance with ASC 718.
+Added: of the restricted shares vested immediately upon grant, and the remaining two-thirds will vest as services are performed.
+Added: year ended December 31, 2025, the Company recognized $ 25,806 of stock-based compensation related to the immediate vesting of 4,600 shares
+Added: upon the grant date.
+Added: As of December 31, 2025, 4,600 shares had been issued and outstanding.
+Added: agreement also provides for milestone-based payments to be settled in shares of the Company’s common stock, with 50% of the shares
+Added: issued as restricted stock and 50% issued as freely tradeable shares.
+Added: The number of shares issuable upon achievement of each milestone
+Added: is based on the trailing five-day average closing price at the time of each milestone achievement.
+Added: expense for these milestone grants is recognized as services are rendered.
+Added: These awards are classified as liabilities until the shares
+Added: are issued, at which point the awards are reclassified to equity.
+Added: During the year ended December 31, 2025, the Company recognized $ 600,000
+Added: of research and development expense related to milestone progression for awards to be settled in shares.
+Added: As of December 31, 2025, 468,750
+Added: shares had been issued pursuant to these milestone-based awards.
Company’s current lease agreement (as amended) has a term that extends through October 31, 2026, with no option to renew.
1 unchanged sentence
The Company recognized total rent expense of $ 36,590 and $ 35,217 in the
−Removed: year ended December 31, 2024, and 2023, respectively.
+Added: years ended December 31, 2025, and 2024, respectively.
8 - NOTES PAYABLE
1 unchanged sentence
SCHEDULE OF DEBT
−Removed: Principal balance
−Removed: Accrued interest
−Removed: Net debt balance
−Removed: 14,368 ( 1,197,200
Financed insurance
following table provides a summary of the Company’s outstanding debt as of December 31, 2024:
−Removed: Unamortized Debt
−Removed: Discount & Issuance Costs
−Removed: $ ( 1,197,200 )
Financed insurance
−Removed: $ ( 1,197,200 )
interest expense recognized for financed insurance was $ 6,375 and $ 8,848 for the year ended December 31, 2025 and 2024, respectively.
1 unchanged sentence
which consists of amortization of the debt discount and debt issuance costs and accrued interest.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
October 23, 2023, the Company entered into a Securities Purchase Agreement (“SPA”) for an aggregate financing of $ 1.8 million
34 unchanged sentences
stock, both with par value equal to $ 0.0001 .
−Removed: As of December 31, 2024, and December 31, 2023, there were no shares of preferred stock
−Removed: issued and outstanding.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
−Removed: November 27, 2024, the Company filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (as
−Removed: amended to date, the “Certificate of Incorporation”), with the Secretary of State of the State of Delaware to effect a one-for-fifteen
−Removed: ( 1-for-15 ) reverse stock split (the “Reverse Stock Split”) of our common stock, par value $ 0.0001 (the “Common Stock”).
−Removed: The Reverse Stock Split was effective as of 12:01 am on December 6, 2024.
−Removed: described in detail in our definitive proxy statement filed with the SEC on October 18, 2024, the Board authorized a 1-for-15 reverse
−Removed: stock split ratio and directed the implementation of the Reverse Stock Split.
−Removed: As a result of the Reverse Stock Split, at the Effective
−Removed: Time, every fifteen (15) shares of our pre-Reverse Stock Split Common Stock will be combined and reclassified into one (1) share of our
+Added: As of December 31, 2025, 4,500 shares have been designated as Series B Preferred Stock.
+Added: The remaining authorized preferred shares are undesignated and available for future issuance.
+Added: As of December 31, 2025, the Company had
+Added: convertible preferred stock as follows:
+Added: SCHEDULE OF CONVERTIBLE PREFERRED STOCK
+Added: Shares Issued
+Added: of December 31, 2024, there were no shares of preferred stock issued and outstanding.
+Added: B Preferred Stock Financing
+Added: November 13, 2025, the Company entered into a Securities Purchase Agreement with an institutional investor (the “Purchaser”)
+Added: providing for (i) a registered direct offering and (ii) a concurrent private placement (collectively, the “Offerings”) for
+Added: aggregate financing of $ 4.0 million.
+Added: the registered direct offering, the Company issued 1,513 shares of Series B Preferred Stock convertible to 665,922 shares of the Company’s
common stock.
−Removed: The post-Reverse Stock Split Common Stock began trading on December 6, 2024, with a new CUSIP number of 293602504.
−Removed: Reverse Stock Split does not affect any stockholder’s ownership percentage of the Common Stock and does not change our authorized
−Removed: number of shares, alter the par value of the Common Stock or modify any voting rights or other terms of the Common Stock.
−Removed: exercise prices, and the number of shares of Common Stock issuable upon exercise of the Company’s warrants automatically adjusted,
−Removed: in accordance with their terms, in proportion to the Reverse Stock Split ratio, and proportionate adjustments were also made to the per
−Removed: share exercise price and/or the number of shares issuable upon the exercise or vesting of all stock options and restricted stock unit
−Removed: awards issued by the Company and outstanding immediately prior to the effective time of the Reverse Stock Split, which resulted in a
−Removed: proportionate decrease in the number of shares of Common Stock reserved for issuance upon exercise or vesting of such stock options and
−Removed: restricted stock unit awards, and a proportionate increase in the exercise price of all such stock options and restricted stock unit
−Removed: Concurrently, the number of shares reserved for issuance under the Company’s Amended and Restated 2021 Omnibus Incentive
−Removed: Plan immediately prior to the effective time of the Reverse Stock Split were reduced proportionately.
−Removed: fractional shares were issued in connection with the Reverse Stock Split.
−Removed: In lieu of the issuance of fractional shares, the Company
−Removed: rounded up any fractional shares resulting from the Reverse Stock Split to the nearest whole share.
−Removed: Fractional shares will be rounded
−Removed: up at the participant (per broker) level, with such rounding adjustment subject to each broker’s particular processes.
+Added: In the concurrent private placement, the Company issued 2,487 unregistered shares of Preferred Stock convertible into 1,094,078
+Added: shares of common stock, subject to adjustment, and warrants to purchase up to 880,000 shares of common stock, subject to adjustment.
+Added: The Series B Preferred Stock has a stated value of $ 1,100 per share.
+Added: The preferred stock and common stock both have par values of $ 0.0001
+Added: Warrants have an exercise price of $ 2.50 per share, subject to customary anti-dilution adjustments, are exercisable beginning six months
+Added: after issuance, and expire on the fifth anniversary of the later of (i) the effectiveness of a resale registration statement covering
+Added: the Warrants and (ii) receipt of required stockholder approval.
+Added: Series B Preferred Stock has the following rights and privileges:
+Added: - Holders of preferred shares shall have no voting rights, except as required by Delaware law and Company’s Certificate of
+Added: To the extent required under the Delaware General Corporation Law, holders of the preferred shares are entitled to vote
+Added: as a separate class (or series, if applicable) to approve certain corporate actions.
+Added: Approval of such matters requires the affirmative
+Added: vote or written consent of the holders of a majority of the outstanding preferred shares voting together as a single class, unless separate
+Added: series voting is required by law.
+Added: In matters where preferred shareholders are entitled to vote together with common shareholders as a
+Added: single class, each preferred share is entitled to the number of votes equal to the number of shares of common stock into which it is
+Added: then convertible, subject to applicable beneficial ownership limitations.
+Added: - Holders of preferred shares shall accrue dividends at a rate of 4.0 % per annum, computed on the basis of a 360-day year consisting
+Added: of twelve 30-day months.
+Added: Dividends accrue daily and are payable in arrears on the first trading day of each fiscal quarter.
+Added: are not payable in cash but are capitalized and added to the stated value of the preferred shares on each dividend payment date.
+Added: dividends are included in the conversion amount upon conversion of the preferred shares and are payable upon certain bankruptcy triggering
+Added: Upon the occurrence and continuation of a triggering event, as defined in the agreement, the dividend rate increases to 8.0%
+Added: per annum until such triggering event is cured.
+Added: - In the event of a liquidation, dissolution or winding up of the Company, holders of preferred shares are entitled to receive, prior
+Added: to any distribution to holders of Junior Stock (shares of capital stock that are junior in rank to all preferred shares with respects
+Added: to preferences of dividends, distributions and payments upon distribution.) and pari passu with holders of any outstanding Parity Stock,
+Added: a cash payment per Preferred Share equal to the greater of (i) 125 % of the applicable Conversion Amount or (ii) the amount that would
+Added: have been received if such Preferred Shares had been converted into Common Stock immediately prior to the Liquidation Event.
+Added: assets are insufficient to pay the full liquidation preference to holders of Preferred Shares and Parity Stock, such amounts will be
+Added: distributed ratably among such holders in proportion to their respective full liquidation preference entitlements.
+Added: The Company is required
+Added: to take all actions, including causing its subsidiaries to distribute available proceeds to the extent permitted by law, to ensure that
+Added: such liquidation preferences are satisfied before any distributions are made to holders of Junior Stock.
+Added: Price Per Share:
+Added: Each share of Series B Preferred Stock is convertible, at the option of the holder, into shares of common stock.
+Added: The number of shares issuable upon conversion is determined by dividing the conversion amount by the conversion price.
+Added: The conversion
+Added: amount equals the stated value of $ 1,100 per share, plus accrued and unpaid dividends and any other amounts owed under the applicable
+Added: transaction documents.
+Added: Upon receipt of a valid conversion notice, the Company is required to issue the applicable number of shares of common stock within one
+Added: trading day, subject to applicable settlement requirements.
+Added: Conversions are subject to a beneficial ownership limitation following conversion.
+Added: conversion price is initially $ 2.50 per share, subject to adjustment.
+Added: At the holder’s election, the conversion price may be adjusted
+Added: to 95% of the lowest volume-weighted average price (“VWAP”) of the Company’s common stock during the five trading days
+Added: preceding conversion, subject to a floor price of $0.4104.
+Added: Conversions are subject to customary beneficial ownership limitations.
+Added: Conversion Upon a Triggering Event - Following the occurrence of a triggering event, holders may elect to convert Series B Preferred
+Added: Stock at an alternate conversion price equal to 90 %
+Added: of the lowest VWAP over the five trading days preceding the conversion date, subject to a floor price of $ 0.4104 .
+Added: Exchange Right - The holder has the right,
+Added: in connection with a subsequent financing by the Company, to apply the stated value of the preferred stock at 120 % of the applicable
+Added: conversion amount toward the purchase price of securities issued in such subsequent placement.
+Added: Purchase Right - The Preferred Stock includes participation rights that entitle each holder of preferred stock to participate in
+Added: any pro rata distribution of options, convertible securities, warrants or other purchase rights granted to holders of Common Stock (other
+Added: than equity awards issued under the Omnibus Incentive Plan).
+Added: In such events, each holder is entitled to receive the amount of such rights
+Added: the holder would have received if all Preferred Shares were converted into Common Stock at the Alternate Conversion Price as of the applicable
+Added: record date, without regard to conversion limitations.
+Added: Participation is subject to the beneficial ownership limitation.
+Added: To the extent
+Added: participation would cause a holder and its attribution parties to exceed such limitation, the excess portion is held in abeyance and
+Added: becomes exercisable when such participation would no longer result in exceeding the beneficial ownership limitation.
+Added: Anti-dilution:
+Added: The Series B Preferred Stock includes price-based anti-dilution protections that adjust the conversion price upon future issuances
+Added: of equity or equity-linked securities at prices below the then-effective conversion price, including issuances of options or convertible
+Added: securities and variable-price securities.
+Added: Company evaluated the terms of the Series B Preferred Stock for embedded features that may require bifurcation as derivative instruments
+Added: under ASC 815.
+Added: Certain features were identified that met the definition of a derivative.
+Added: However, the Company concluded that the fair
+Added: value of such features was not material to the financial statements and accordingly did not recognize them as separate derivative liabilities.
+Added: The Company will continue to reassess this conclusion at each reporting period.
+Added: April Warrant Inducement
+Added: April 2025, the Company entered into an Inducement Letter with certain warrant holders for the exercise of certain outstanding warrants
+Added: to purchase up to an aggregate of 630,376 shares of common stock of the Company, par value $ 0.0001 per share.
+Added: The warrants were issued
+Added: in March 2025 and have an exercise price of $ 3.24 share.
+Added: The shares of common stock issuable upon exercise of such outstanding warrants
+Added: are registered pursuant to an effective registration statement on Form S-3.
+Added: consideration for the immediate exercise of the warrants for cash and the payment of an additional $ 0.125 per new unregistered warrant
+Added: (an additional $ 157,594 included in the gross proceeds to the Company), pursuant to the Inducement Agreement, the Company agreed to issue
+Added: and sell unregistered warrants to purchase shares of common stock.
+Added: The new warrants (the “ Common Warrants ”) are exercisable
+Added: for an aggregate of up to 1,260,752 shares of common stock.
+Added: The Common Warrants have an exercise price of $ 1.90 per share and are immediately
+Added: exercisable for shares of common stock.
+Added: One half of the Common Warrants will expire after eighteen ( 18 ) months and the other half will
+Added: expire after five ( 5 ) years.
+Added: The gross proceeds to the Company from the exercise of the warrants and payment for Common Warrants was
+Added: approximately $ 2.2 million, prior to deducting placement agent fees and estimated offering expenses.
+Added: Company utilized a placement agent for the 2025 April Warrant Inducement and incurred approximately $ 0.3 million in legal fees and other
+Added: closing costs.
+Added: Additionally, the Company issued to the placement agent as compensation unregistered warrants to purchase up to 44,126
+Added: shares of common stock, equal to 7.0% of the aggregate number of shares of Common Stock (or warrants) placed in the transaction.
+Added: placement agent warrants expire on April 24, 2030 , and have an exercise price of $ 4.05 per share of common stock.
+Added: The closing of the
+Added: offering occurred on April 24, 2025.
+Added: Registered Direct Offering and 2025 March Warrant Offering
+Added: March 2025, the Company entered into a definitive SPA with certain institutional investors, pursuant to which the Company agreed to issue
+Added: and sell in a registered direct offering, (i) an aggregate of 239,594 shares of common stock, par value $ 0.0001 per share at an offering
+Added: price of $ 3.49 per share, (ii) pre-funded warrants to purchase up to 75,594 shares of common stock, at a price per pre-funded warrant
+Added: equal to $ 3.4899 , the price per share less $ 0.0001 , for gross proceeds of approximately $ 1.1 million before the deduction of placement
+Added: agent fees and offering expenses.
+Added: The pre-funded warrants were fully exercised as of March 31, 2025, and the related common shares were
+Added: issued in April 2025.
+Added: a concurrent private placement, pursuant to the terms of the SPA, the Company also agreed to issue and sell unregistered warrants to
+Added: purchase up to 315,188 shares of Common Stock (the “ Series A-5 Warrants ”), and Series A-6 warrants to purchase up
+Added: to 315,188 shares of Common Stock (the “ Series A-6 Warrants ”), to purchase up to an aggregate 630,376 shares of Common
+Added: The warrants have an exercise price of $ 3.24 per share and are exercisable immediately.
+Added: The Series A-5 Warrants will expire eighteen
+Added: (18) months after issuance and the Series A-6 Warrants will expire five ( 5 ) years after issuance.
Registered Direct Offering and 2024 August Warrant Inducement
26 unchanged sentences
adjustments to the exercise price, including for share splits, share dividends, rights offering and pro rata distributions.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
February Warrant Inducement
28 unchanged sentences
The closing of the offering occurred on February 14, 2024.
−Removed: May 12, 2023, the Company completed a public offering of an aggregate of 120,059 shares of its common stock at par value $ 0.0001 per
−Removed: share (including pre-funded warrants in lieu thereof) at a combined offering price of $ 58.305 per share, gross proceeds from this offering
−Removed: were approximately $ 7.0 million before the deduction of placement agent fees and related costs of $ 0.7 million.
−Removed: The warrants issued in
−Removed: connection with the 2023 May Offering are described further below.
−Removed: connection with the offering, the Company also agreed to amend certain existing warrants to purchase up to an aggregate of 14,006 shares
−Removed: of the Company’s common stock that were previously issued in September 2021 through December 2022 to purchasers in the offering
−Removed: at exercise prices ranging from $ 252.00 to $ 2,808.00 per share, such that effective upon the closing of the offering, the amended warrants
−Removed: had a reduced exercise price of $ 54.60 per share at an additional offering price of $ 1.875 per amended warrant.
−Removed: February Offering
−Removed: February 2, 2023, the Company agreed to issue and sell in a registered direct offering an aggregate of 19,842 shares of common stock
−Removed: of the Company, par value $ 0.0001 per share, at an offering price of $ 151.20 per share, for gross proceeds of approximately $ 3.0 million
−Removed: before the deduction of placement agent fees and related costs of $ 0.3 million.
−Removed: The closing occurred on February 6, 2023.
−Removed: issued in connection with the 2023 February Offering are described further below.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
following table provides a summary of outstanding warrants to purchase shares of common stock as of December 31, 2025:
−Removed: OF OUTSTANDING WARRANT
−Removed: Underlying Outstanding Warrants
+Added: SCHEDULE OF OUTSTANDING WARRANT
+Added: Shares Underlying
+Added: Exercise Price
Classification
+Added: $ 2.50 - $ 3.125
+Added: November 2025 Warrants
+Added: $ 1.90 - $ 4.05
+Added: April 2025 Warrants
+Added: March 2025 Warrants
+Added: $ 7.05 - $ 8.8125
August 2024 Warrants
February 2024 Warrants
+Added: $ 7.05 - $ 23.51
2023 Notes Warrants
+Added: $ 54.56 - $ 41,400
Other Warrants
Equity & Liability
+Added: November 14, 2025, the Company issued 880,000 equity classified warrants to certain institutional investors with the Series B Preferred
+Added: Stock Financing.
+Added: The warrants have an exercise price of $ 2.50 per share and are immediately exercisable for shares of common stock
+Added: and expire on January 7, 2031 .
+Added: In connection with the Series B Preferred Stock Financing, there were 112,000 warrants issued to placement
+Added: The placement agent warrants were immediately exercisable with an exercise price of $ 3.125 per share and expire on January
+Added: April 24, 2025, the Company issued 1,304,878 equity classified warrants (Common Warrants and placement agent warrants) in connection
+Added: with the Inducement Letter of the 2025 April warrant inducement.
+Added: The Common Warrants have an exercise price of $ 1.90 per share and
+Added: are immediately exercisable for shares of common stock.
+Added: One half of the Common Warrants will expire on October 26, 2026 , and the
+Added: other half will expire on April 24, 2030 .
+Added: The placement agent warrants were immediately exercisable with an exercise price of $ 4.05
+Added: per share and expire on April 24, 2030 .
+Added: During the year ended December 31, 2025, there were 1,170,564 warrants exercised at an exercise
+Added: price of $ 1.90 per share.
+Added: March 31, 2025, in connection with the 2025 Registered Direct Offering and 2025 March Warrant Offering, the Company issued equity
+Added: classified warrants to purchase 652,439 shares to certain institutional investors and the placement agent.
+Added: The warrants were issued
+Added: in connection with the 2025 Registered Direct Offering and 2025 March Warrant Offering.
+Added: The 630,376 investor warrants have an exercise
+Added: price of $ 3.24 per share.
+Added: One half of the warrants will expire on October 1, 2026 , and the other half will expire on March 31, 2030.
+Added: The 22,063 placement agent warrants have an exercise price of $ 4.3625 per share and expire on March 30, 2030 .
+Added: In connection with
+Added: the 2025 April Warrant Inducement, 630,376 investor warrants were exercised.
+Added: As of December 31, 2025, the placement agents remain
August 29, 2024, in connection with the 2024 Registered Direct Offering and 2024 August Warrant Inducement , the Company
2 unchanged sentences
The 1,914,466 investor
−Removed: warrants have an exercise price of $ 7.05 per share and are exercisable from the date on which stockholder approval is received.
−Removed: half of the warrants will expire eighteen months after they are exercisable, and the other half will expire five years after they
−Removed: are exercisable.
−Removed: The 50,200 placement agent warrants have an exercise price of $ 8.8125 per share, are exercisable upon stockholder
−Removed: approval and expire August 28, 2029 .
−Removed: In December 2024, 50,760 investor warrants were exercised.
−Removed: February 12, 2024, the Company issued 497,042 equity classified warrants (Series A Warrants,
−Removed: Series B Warrants and placement agent warrants) in connection with the Inducement Letter
−Removed: for the 2024 February warrant inducement and related warrant restructuring.
−Removed: and Series B Warrants were immediately exercisable with an exercise price of $ 15.90 per share
−Removed: and expire on August 14, 2025 and May 12, 2028 , respectively.
−Removed: The placement agent warrants
−Removed: were immediately exercisable with an exercise price of $ 24.56 per share and expire on May
−Removed: In connection with the 2024 August Warrant Inducement, 480,234 warrants were exercised.
+Added: warrants have an exercise price of $ 7.05 per share.
+Added: One half of the warrants expire on May 21, 2026 , and the other half expire on
+Added: November 21, 2029 .
+Added: The 50,200 placement agent warrants have an exercise price of $ 8.8125 per share and expire on August 28, 2029 .
+Added: In December 2024 and January 2025, investor warrants of 50,760 and 49,361 , respectively, were exercised.
+Added: February 12, 2024, the Company issued 497,047 equity classified warrants (Series A Warrants, Series B Warrants and placement agent
+Added: warrants) in connection with the Inducement Letter for the 2024 February warrant inducement and related warrant restructuring.
+Added: Series A and Series B Warrants were immediately exercisable with an exercise price of $ 15.90 per share and expire on August 14, 2025
+Added: and May 12, 2028 , respectively.
+Added: The placement agent warrants were immediately exercisable with an exercise price of $ 24.56 per share
+Added: and expire on May 12, 2028.
+Added: In connection with the 2024 August Warrant Inducement, 480,236 Series A and Series B warrants were exercised.
As of December 31, 2025, the placement agents remain outstanding.
−Removed: October 25, 2023, and November 28, 2023, the Company issued warrants to purchase 83,714 shares
−Removed: and 167,427 shares, respectively.
−Removed: The warrants were immediately exercisable with an exercise
−Removed: price of $ 23.51 per share and expire on October 25, 2028 , and November 28, 2028 , respectively.
−Removed: In January 2024, a holder of the warrants exercised 88,261 warrants at an exercise price
−Removed: of $ 23.51 per share.
−Removed: In August 2024, an inducement letter was issued to a holder of 133,334
−Removed: warrants to reduce the exercise price from $ 23.51 to $ 7.05 per share.
+Added: October 25, 2023, and November 28, 2023, the Company issued warrants to purchase 83,714 shares and 167,428 shares, respectively.
+Added: The warrants were immediately exercisable with an exercise price of $ 23.51 per share and expire on October 25, 2028, and November
+Added: 28, 2028 , respectively.
+Added: In January 2024, a holder of the warrants exercised 88,261 warrants at an exercise price of $ 23.51 per share.
+Added: In August 2024, an inducement letter was issued to a holder of 133,334 warrants to reduce the exercise price from $ 23.51 to $ 7.05
various dates from the Closing of the Business Combination through September 30, 2023, the Company assumed or issued a total of 73,474
warrants to provide holders the right to purchase common stock at exercise prices ranging from $ 54.60 - $ 41,400 per share.
−Removed: of 2,778 of the outstanding warrants are public warrants which trade on the OTC Pink Open Market under the ticker symbol ENSCW.
−Removed: total of 2,901 outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified due to certain cash
−Removed: settlement features embedded within the warrant agreements.
+Added: of 2,778 of the outstanding warrants are public warrants which trade on the Pink Limited Market operated by OTC Markets Group Inc.
+Added: under the ticker symbol ENSCW.
+Added: A total of 2,901 outstanding warrants (issued in connection with the 2021 and 2022 Notes) are liability-classified
+Added: due to certain cash settlement features embedded within the warrant agreements.
The remaining warrants are equity classified.
−Removed: The warrants expire beginning
−Removed: June 30, 2026 , through August 7, 2028
+Added: warrants expire beginning June 30, 2026, through August 7, 2028 .
10 - STOCK-BASED COMPENSATION
2 unchanged sentences
Board approved an annual increase of 67,789 shares available for future grant under the 2021 Omnibus Plan.
−Removed: Company recognized within general and administrative expense stock-based compensation expense of $ 75,494 and $ 627,406 for the year ended
+Added: Company recognized within general and administrative expense stock-based compensation expense of $ 118,674 and $ 75,494 for the years ended
December 31, 2025 and 2024, respectively.
−Removed: During the year ended December 31, 2024 and 2023, the company recognized within research and
+Added: During the years ended December 31, 2025 and 2024, the company recognized within research and
development expense stock-based compensation expense of $ 691,893 and $ 35,229 , respectively.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
−Removed: the year ended December 31, 2024, the Company did not grant any stock options.
−Removed: During the year ended December 31, 2023, the Company granted
−Removed: stock options to purchase an aggregate of 37,000 shares of common stock to employees and members of the board of directors.
−Removed: vested immediately and have an exercise price of between $ 16.95 and $ 17.70 per share.
−Removed: following table summarizes the Company’s stock option activity during the year ended December 31, 2024:
+Added: the year ended December 31, 2025, the Company granted stock options to employees and members of the board of directors to purchase an
+Added: aggregate of 64,000 shares of common stock.
+Added: The options vest over one to four years and have an exercise price of $ 2.00 to $ 3.12 per
+Added: The following table summarizes the Company’s stock option activity during the year ended December 31, 2025:
SCHEDULE OF STOCK OPTION ACTIVITY
−Removed: contractual life
+Added: Weighted average
+Added: Exercise price
+Added: Intrinsic value
Outstanding at December 31, 2024
5 unchanged sentences
The material assumptions used
−Removed: in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (no stock options
−Removed: were granted during the year ended December 31, 2024):
+Added: in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows:
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS
+Added: December 31, 2025
Exercise price
+Added: $ 2.00 - 3.12
Expected stock price volatility
+Added: 114.21 % - 141.65 %
Expected term (years)
20 unchanged sentences
to pay any dividends on the Company’s common stock.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
weighted-average grant date fair value of options granted during the year ended December 31, 2025 was $ 2.63 .
4 unchanged sentences
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE
−Removed: Awards outstanding under the 2021
−Removed: Omnibus Incentive Plan
−Removed: Awards available for future grant under 2021
−Removed: Omnibus Incentive Plan
+Added: December 31, 2025
+Added: Awards outstanding under the Plan
+Added: Awards available for future grant under the Plan
Warrants outstanding
−Removed: Total shares of common
−Removed: stock reserved for future issuance
+Added: Shares for consultant compensation agreement outside the Plan
+Added: Conversion of Series B preferred stock
+Added: Total shares of common stock reserved for future issuance
11 - INCOME TAXES
1 unchanged sentence
SCHEDULE OF INCOME TAXES BENEFIT
−Removed: ending December 31,
+Added: Year ending December 31,
United States
1 unchanged sentence
$ ( 7,987,009 )
−Removed: federal and state income tax provision (benefit), included in general and administrative expenses in the Consolidated Statement of Operations,
−Removed: is summarized as follows:
−Removed: SCHEDULE OF FEDERAL AND STATE INCOME TAX PROVISION (BENEFIT)
−Removed: ending December 31,
−Removed: Current state provision
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
+Added: Company has not recorded a current or deferred tax expense or benefit, nor has it paid cash income taxes or received cash income tax
+Added: refunds from any jurisdiction for the years ended December 31, 2025 or 2024.
effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal statutory rate as follows:
SCHEDULE OF FEDERAL INCOME TAX RATE RECONCILIATION
−Removed: ending December 31,
−Removed: Income (benefit) taxes at statutory
+Added: Nontaxable or nondeductible items:
+Added: Year ending December 31,
+Added: Income taxes (benefit) at statutory rates
$ ( 2,136,999 )
$ ( 1,677,271 )
−Removed: State income tax, net of federal benefit
−Removed: Warrants and convertible debt
−Removed: Nondeductible executive compensation
−Removed: Stock based compensation
−Removed: Research and development tax credits
−Removed: Expiring attributes
−Removed: Change in tax rates
+Added: State and local income taxes, net of federal benefit *
Change in valuation allowance
+Added: Nontaxable or nondeductible items:
+Added: Permanent items
+Added: Changes in unrecognized tax benefits
+Added: Expiration of attributes
+Added: Provision for income taxes
+Added: * State taxes in
+Added: California made up the majority (greater than 50 %) of the tax effect in this category for 2025 and 2024.
income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial
2 unchanged sentences
SCHEDULE OF DEFERRED TAX ASSETS
−Removed: of December 31,
+Added: As of December 31,
Deferred tax assets:
−Removed: Net operating
−Removed: loss tax carryforwards
+Added: Net operating loss tax carryforwards
Capitalized research costs
6 unchanged sentences
Deferred tax liabilities:
−Removed: deferred tax liabilities
+Added: Total deferred tax liabilities
Net deferred tax assets
+Added: valuation allowance of approximately $ 42.5 million as of December 31, 2025 has been established to offset the deferred tax assets as
+Added: the Company has determined that it is not more likely than not that these assets will be realized.
+Added: The valuation allowance increased
+Added: by approximately $ 2.1 million during 2025.
of December 31, 2025, the Company had federal and California net operating loss (NOL) carryforwards of $ 130.5 million and $ 76.9 million,
5 unchanged sentences
The California NOL carryforwards will begin to expire in 2028 , unless previously utilized.
−Removed: Biosciences, Inc.
−Removed: to the Consolidated Financial Statements
addition, as of December 31, 2025, the Company had federal and state research and development (R&D) tax credit carryforwards of $ 6.1
14 unchanged sentences
following table summarizes the activity related to the Company’s unrecognized tax benefits:
−Removed: OF UNRECOGNIZED TAX BENEFITS
−Removed: ending December 31,
+Added: SCHEDULE OF UNRECOGNIZED TAX BENEFITS
+Added: Year ending December 31,
Balance at beginning of year
1 unchanged sentence
Increases related to prior year tax positions
−Removed: Decreases related to prior
−Removed: year tax positions
+Added: Decreases related to prior year tax positions
Balance at end of year
6 unchanged sentences
for the years ended December 31, 2025 or 2024 and had no accrued interest on the consolidated balance sheets as of December 31, 2025
−Removed: The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within
−Removed: twelve months of the reporting date.
Company and its subsidiaries are subject to U.S.
6 unchanged sentences
is not currently under examination by the Internal Revenue Service or any state or local tax authority.
+Added: July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was signed into law, which enacts significant changes to U.S.
+Added: and related laws.
+Added: Some of the provisions of the new tax law affecting corporations include, but are not limited to, expensing of domestic
+Added: research expenses, increasing the limit of the deduction of interest expense deduction to thirty percent of EBITDA, and one hundred percent
+Added: bonus depreciation on eligible property acquired after January 19, 2025.
+Added: The provisions of the OBBBA became effective for the Company
+Added: during the three months ended September 30, 2025.
+Added: The new tax law did not have a material impact on the Company’s current or future
+Added: effective rate for income taxes or cash taxes paid.
12 - RELATED PARTIES
2 unchanged sentences
2025, the Company and the board member entered into a forbearance agreement that will expire on April 25, 2026 .
−Removed: Upon termination
−Removed: of the forbearance period, the Company will owe the remaining outstanding principal balance together with unpaid interest.
−Removed: may pay the notes in full at any time prior to the conclusion of the forbearance period.
+Added: Upon termination of the
+Added: forbearance period, the Company will owe the remaining outstanding principal balance together with unpaid interest.
+Added: The Company may pay
+Added: the notes in full at any time prior to the conclusion of the forbearance period.
13 - SUBSEQUENT EVENTS
−Removed: January 2025, the Company issued 49,361 shares of common stock for $ 0.3 million upon exercise of August 2024 warrants issued.
−Removed: January 2025, the Company entered into a product development and supply agreement with Galephar Pharmaceutical Research, Inc., a Puerto
−Removed: Rico specialty drug manufacturer (“Galephar”).
−Removed: Galephar will support the development, manufacture, packaging and testing
−Removed: of the Company’s PF614 and PF614-MPAR drug products for use in clinical trials and potential future commercial launch.
−Removed: will pay Galephar upon achievement of defined milestones at up to 1.2 times Galephar’s costs, subject to a cap.
−Removed: Payment will be
−Removed: in the form of common stock at fifty percent (50%) restricted shares and fifty percent (50%) freely tradeable registered shares, with
−Removed: the number of shares to be issued by the Company determined by the trailing five-day average closing price of the Company’s common
−Removed: stock upon achievement of each milestone.
−Removed: In addition, the Company will issue up to 13,801 shares ( 1 % of shares outstanding upon signing of agreement)
−Removed: of restricted common stock to Galephar with vesting in three tranches through completion of defined milestones.
−Removed: and Plan of Merger, dated January 31, 2021, by and among Leisure Acquisition Corp., Ensysce Biosciences, Inc.
−Removed: and EB Merger Sub,
−Removed: (incorporated by reference to Exhibit 2.1 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279)
−Removed: initially filed on March 15, 2021).
−Removed: Amended and Restated Certificate of Incorporation of Ensysce Biosciences, Inc.
−Removed: (incorporated by reference to Exhibit 3.1 filed with
−Removed: the registrant’s Current Report on Form 8-K on July 7, 2021).
−Removed: of amendment to Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1(b) filed with the
−Removed: registrant’s Registration Statement on Form S-1 (File No.
+Added: January 2026, shareholders approved an increase of 600,000 shares available for future grant under the 2021 Omnibus Incentive Plan.
+Added: February 2026, the Board approved an annual increase of 228,749 shares available for future grant per terms of the 2021 Omnibus Incentive
+Added: January 1, 2026, the Company issued 4.7 million shares of common stock upon the conversion of 1,900 shares of Series B Preferred Stock.
+Added: Agreement and Plan of Merger, dated January 31, 2021, by and among Leisure Acquisition Corp., Ensysce Biosciences, Inc.
+Added: and EB Merger Sub, Inc.
+Added: (incorporated by reference to Exhibit 2.1 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021).
+Added: Third Amended and Restated Certificate of Incorporation of Ensysce Biosciences, Inc.
+Added: (incorporated by reference to Exhibit 3.1 filed with the registrant’s Current Report on Form 8-K on July 7, 2021).
+Added: Certificate of amendment to Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1(b) filed with the registrant’s Registration Statement on Form S-1 (File No.
333-268038) on October 28, 2022)
−Removed: of Second Amendment to Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 filed with
−Removed: the registrant’s Current Report on Form 8-K (File No.
+Added: Certificate of Second Amendment to Third Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on October 27, 2022)
−Removed: of Designation of the Series A Preferred Stock of Ensysce Biosciences, Inc., dated February 1, 2023 (incorporated by reference to
−Removed: Exhibit 3.1 to the registrant’s Registration Statement on Form 8-A, filed on February 1, 2023, File No.
−Removed: of Amendment to Certificate of Designation of the Series A Preferred Stock of Ensysce Biosciences, Inc., dated February 7, 2023 (incorporated
−Removed: by reference to Exhibit 3.2 to the Company’s Registration Statement on Form 8-A/A (Amendment No.
−Removed: 1), filed on February 7, 2023,
−Removed: and Restated Bylaws of Ensysce Biosciences, Inc.
−Removed: (incorporated by reference to Exhibit 3.2 filed with the registrant’s Current
−Removed: Report on Form 8-K on July 7, 2021)
−Removed: to Amended and Restated Bylaws of Ensysce Biosciences, Inc.
−Removed: (incorporated by reference to Exhibit 3.2(b) filed with the registrant’s
−Removed: Current Report on Form 8-K on October 15, 2024)
−Removed: Agreement, dated December 1, 2017, between the Leisure Acquisition Corp.
−Removed: and Continental Stock Transfer & Trust Company (incorporated
−Removed: by reference to Exhibit 4.1 filed with the registrant’s Current Report on Form 8-K on December 5, 2017)
−Removed: Rights Agreement between Ensysce Biosciences, Inc.
−Removed: and the Investors listed on the signature pages thereto dated as of May 11, 2018
−Removed: (incorporated by reference to Exhibit 4.6 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279)
−Removed: initially filed on March 15, 2021)
−Removed: of Warrant Certificate issued to previous holders of Private Placement Warrants and other private warrants (incorporated by reference
−Removed: to Exhibit 4.8 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March
−Removed: of Common Stock Purchase Warrant to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement
−Removed: (incorporated by reference to Exhibit 4.7 filed with the registrant’s Current Report on Form 8-K initially filed on September
−Removed: of Common Stock Purchase Warrant issued by Ensysce Biosciences, Inc.
−Removed: pursuant to and in accordance with a 2022 Securities Purchase
−Removed: Agreement (incorporated by reference to Exhibit 4.7 filed with the registrant’s Current Report on Form 8-K on August 9, 2022)
+Added: Certificate of Designation of Series B Preferred Stock of Ensysce Biosciences, Inc., dated November 14, 2025, including Certificate of Correction to the Certificate of Designation dated November 14, 2025 (incorporated by reference to Exhibit 4.1 to the registrant’s Current Report on Form 8-K filed on November 17, 2025)
+Added: Amended and Restated Bylaws of Ensysce Biosciences, Inc.
+Added: (incorporated by reference to Exhibit 3.2 filed with the registrant’s Current Report on Form 8-K on July 7, 2021)
+Added: Amendment to Amended and Restated Bylaws of Ensysce Biosciences, Inc.
+Added: (incorporated by reference to Exhibit 3.2(b) filed with the registrant’s Current Report on Form 8-K on October 15, 2024)
+Added: Warrant Agreement, dated December 1, 2017, between the Leisure Acquisition Corp.
+Added: and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 filed with the registrant’s Current Report on Form 8-K on December 5, 2017)
+Added: Investor Rights Agreement between Ensysce Biosciences, Inc.
+Added: and the Investors listed on the signature pages thereto dated as of May 11, 2018 (incorporated by reference to Exhibit 4.6 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
+Added: Form of Warrant Certificate issued to previous holders of Private Placement Warrants and other private warrants (incorporated by reference to Exhibit 4.8 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
+Added: Form of Common Stock Purchase Warrant to be issued by the Company pursuant to and in accordance with the Securities Purchase Agreement (incorporated by reference to Exhibit 4.7 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
+Added: Form of Common Stock Purchase Warrant issued by Ensysce Biosciences, Inc.
+Added: pursuant to and in accordance with a 2022 Securities Purchase Agreement (incorporated by reference to Exhibit 4.7 filed with the registrant’s Current Report on Form 8-K on August 9, 2022)
Form of warrant delivered by Ensysce Biosciences, Inc.
1 unchanged sentence
1 to the registrant’s Registration Statement on Form S-1 filed December 8, 2022)
−Removed: of pre-funded warrant delivered by Ensysce Biosciences, Inc.
−Removed: in December 2022 in connection with an underwritten offering (incorporated
−Removed: by reference to Exhibit 4.11 filed with the registrant’s Post-Effective Amendment No.
−Removed: 1 to the registrant’s Registration
−Removed: Statement on Form S-1 filed December 8, 2022)
−Removed: of warrant issued in connection with a private placement conducted concurrently with a public offering (incorporated by reference
−Removed: to Exhibit 4.1 filed with the registrant’s Current Report on Form 8-K on February 7, 2023)
−Removed: of warrant issued to a placement agent or its designees in connection with a private placement conducted concurrently with a public
−Removed: offering (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K on February 7, 2023)
−Removed: of common warrant (incorporated by reference to Exhibit 4.12 filed with the registrant’s Post-Effective Amendment No.
−Removed: the Registration Statement on Form S-1 (File No.
−Removed: 333-271480) on May 17, 2023)
−Removed: of pre-funded warrant (incorporated by reference to Exhibit 4.13 filed with the registrant’s Post-Effective Amendment No.
+Added: Form of warrant issued in connection with a private placement conducted concurrently with a public offering (incorporated by reference to Exhibit 4.1 filed with the registrant’s Current Report on Form 8-K on February 7, 2023)
+Added: Form of warrant issued to a placement agent or its designees in connection with a private placement conducted concurrently with a public offering (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K on February 7, 2023)
+Added: Form of common warrant (incorporated by reference to Exhibit 4.12 filed with the registrant’s Post-Effective Amendment No.
1 to the Registration Statement on Form S-1 (File No.
333-271480) on May 17, 2023)
−Removed: of placement agent warrant (incorporated by reference to Exhibit 4.14 filed with the registrant’s Post-Effective Amendment
−Removed: on Form S-1 (File No.
+Added: Form of placement agent warrant (incorporated by reference to Exhibit 4.14 filed with the registrant’s Post-Effective Amendment on Form S-1 (File No.
333-271480) on May 17, 2023)
−Removed: of warrants amended in connection with the execution of a Securities Purchase Agreement on May 10, 2023 (incorporated by reference
−Removed: to Exhibit 4.15 filed with the registrant’s Post-Effective Amendment No.
−Removed: 1 to the Registration Statement on Form S-1 (File
+Added: Form of warrants amended in connection with the execution of a Securities Purchase Agreement on May 10, 2023 (incorporated by reference to Exhibit 4.15 filed with the registrant’s Post-Effective Amendment No.
+Added: 1 to the Registration Statement on Form S-1 (File No.
333-271480) on May 17, 2023)
−Removed: of common warrant issued in October 2023 and November 2023 (incorporated by reference to Exhibit 4.16 filed with the registrant’s
−Removed: Registration Statement on Form S-1 (File No.
+Added: Form of common warrant issued in October 2023 and November 2023 (incorporated by reference to Exhibit 4.16 filed with the registrant’s Registration Statement on Form S-1 (File No.
333-275456) on November 9, 2023)
−Removed: of October 2023 Secured Convertible Promissory Note (incorporated by reference to Exhibit 4.6 filed with the registrant’s Current
−Removed: Report on Form 8-K (File No.
+Added: Form of October 2023 Secured Convertible Promissory Note (incorporated by reference to Exhibit 4.6 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on October 24, 2023).
−Removed: of Series A/B common stock purchase warrant issued February 14, 2024 (incorporated by reference to Exhibit 4.1 filed with the registrant’s
−Removed: Current Report on Form 8-K (File No.
+Added: Form of Series A/B common stock purchase warrant issued February 14, 2024 (incorporated by reference to Exhibit 4.1 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on February 14, 2024)
−Removed: of placement agent warrant issued February 14, 2024 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current
−Removed: Report on Form 8-K (File No.
+Added: Form of placement agent warrant issued February 14, 2024 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on February 14, 2024)
−Removed: Rights Agreement, dated December 1, 2017, among Leisure Acquisition Corp.
−Removed: and certain securityholders (incorporated by reference
−Removed: to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K on December 5, 2017)
−Removed: Purchase Agreement, dated December 1, 2017, between Leisure Acquisition Corp.
−Removed: and certain security holders (incorporated by reference
−Removed: to Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K on December 5, 2017)
−Removed: of Director and Officer Indemnity Agreement (incorporated by reference to Exhibit 10.8 filed with the registrant’s Registration
−Removed: Statement on Form S-1 (File No.333-221330) initially filed on November 3, 2017)
−Removed: of Indemnification Agreement executed by each of the Ensysce directors and executive officers (incorporated by reference to Exhibit
−Removed: 10.6 filed with the registrant’s Form 10-Q initially filed on November 15, 2021)
−Removed: Employment Agreement, by and between the Company and Dr.
−Removed: Lynn Kirkpatrick, dated September 14, 2021 (incorporated by reference to
−Removed: Exhibit 10.44 filed with the registrant’s Amendment Number 1 to its Registration Statement on Form S-1 (File No.333-260478)
−Removed: filed on October 29, 2021)
−Removed: and Plan of Merger by and among the Signature Therapeutics, Inc., Signature Acquisition Corp.
−Removed: and the Company dated December 28,
−Removed: 2015 (incorporated by reference to Exhibit 10.21 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279)
−Removed: initially filed on March 15, 2021)
−Removed: Employment Agreement, by and between the Company and Geoffrey Birkett, dated August 21, 2021 (incorporated by reference to Exhibit
−Removed: 10.45 filed with the registrant’s Amendment Number 1 to its Registration Statement on Form S-1 (File No.333-260478) filed on
−Removed: October 29, 2021)
−Removed: Agreement between the Company and David Humphrey dated February 11, 2021 (incorporated by reference to Exhibit 10.26 filed with the
−Removed: registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
−Removed: to Offer Letter between the Company and David Humphrey dated February 23, 2021 (incorporated by reference to Exhibit 10.27 filed
−Removed: with the the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
+Added: Form of Series A-3/A-4 common stock purchase warrant issued August 29, 2024 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No.
+Added: 001-38306) on August 30, 2024)
+Added: Form of Series A-5/A-6 common stock purchase warrant issued March 31, 2025 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No.
+Added: 001-38306) on March 31, 2025)
+Added: Form of placement agent warrant issued March 31, 2025 (incorporated by reference to Exhibit 4.3 filed with the registrant’s Current Report on Form 8-K (File No.
+Added: 001-38306) on March 31, 2025)
+Added: Form of Series A-7/A-8 common stock purchase warrant issued April 24, 2025 (incorporated by reference to Exhibit 4.1 filed with the registrant’s Current Report on Form 8-K (File No.
+Added: 001-38306) on April 24, 2025)
+Added: Form of placement agent warrant issued April 24, 2025 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K (File No.
+Added: 001-38306) on April 24, 2025)
+Added: Form of Common Stock Purchase Warrant issued November 13, 2025 (incorporated by reference to Exhibit 4.2 filed with the registrant’s Current Report on Form 8-K on November 17, 2025
+Added: Form of Common Stock Purchase Warrant issued November 13, 2025 to a financial advisor or its designees (incorporated by reference to Exhibit 4.24 filed with the registrant’s Registration Statement on Form S-3 (File No.
+Added: 333-291892) filed on December 2, 2025)
+Added: Registration Rights Agreement, dated December 1, 2017, among Leisure Acquisition Corp.
+Added: and certain securityholders (incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K on December 5, 2017)
+Added: Warrant Purchase Agreement, dated December 1, 2017, between Leisure Acquisition Corp.
+Added: and certain security holders (incorporated by reference to Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K on December 5, 2017)
+Added: Form of Director and Officer Indemnity Agreement (incorporated by reference to Exhibit 10.8 filed with the registrant’s Registration Statement on Form S-1 (File No.333-221330) initially filed on November 3, 2017)
+Added: Form of Indemnification Agreement executed by each of the Ensysce directors and executive officers (incorporated by reference to Exhibit 10.6 filed with the registrant’s Form 10-Q initially filed on November 15, 2021)
+Added: Executive Employment Agreement, by and between the Company and Dr.
+Added: Lynn Kirkpatrick, dated September 14, 2021 (incorporated by reference to Exhibit 10.44 filed with the registrant’s Amendment Number 1 to its Registration Statement on Form S-1 (File No.333-260478) filed on October 29, 2021)
+Added: Agreement and Plan of Merger by and among the Signature Therapeutics, Inc., Signature Acquisition Corp.
+Added: and the Company dated December 28, 2015 (incorporated by reference to Exhibit 10.21 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
+Added: Executive Employment Agreement, by and between the Company and Geoffrey Birkett, dated August 21, 2021 (incorporated by reference to Exhibit 10.45 filed with the registrant’s Amendment Number 1 to its Registration Statement on Form S-1 (File No.333-260478) filed on October 29, 2021)
+Added: Employment Agreement between the Company and David Humphrey dated February 11, 2021 (incorporated by reference to Exhibit 10.26 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
+Added: Amendment to Offer Letter between the Company and David Humphrey dated February 23, 2021 (incorporated by reference to Exhibit 10.27 filed with the the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
Amended and Restated 2021 Omnibus Incentive Plan (incorporated by reference to Exhibit Notes filed with the registrant’s Annual Report on Form 10-K filed on March 31, 2022)
−Removed: and Restated 2021 Omnibus Incentive Plan Form of Stock Option Grant Notice and Award Agreement (incorporated by reference to Exhibit
−Removed: 10.22(a) filed with the registrant’s Annual Report on Form 10-K filed on March 31, 2022)
+Added: Amended and Restated 2021 Omnibus Incentive Plan Form of Stock Option Grant Notice and Award Agreement (incorporated by reference to Exhibit 10.22(a) filed with the registrant’s Annual Report on Form 10-K filed on March 31, 2022)
Technology Transfer Agreement by and among the Company, Covistat, Inc., Mucokinetica, Ltd., Roderick Hall and Peter Cole dated August 5, 2020 (incorporated by reference to Exhibit 10.30, filed on April 16, 2021 in an amendment to the registrant’s Registration Statement on Form S-4 (File No.333-254279))
−Removed: Manufacturing
−Removed: Agreement between Recro Gaineville LLC and the Company dated September 11, 2019 (incorporated by reference to Exhibit 10.35 filed
−Removed: with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
−Removed: of Exchange Agreement between Leisure Acquisition Corp.
−Removed: and the holders of Private Placement Warrants (incorporated by reference
−Removed: to Exhibit 10.36(a) filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on
−Removed: March 15, 2021)
−Removed: of Exchange Agreement to be entered into by the Company with each of the Sponsors and the Strategic Investor (incorporated by reference
−Removed: to Exhibit 10.36(b) filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on
−Removed: March 15, 2021)
−Removed: Purchase Agreement, dated September 24, 2021 by and among the Company and the purchasers signatory thereto (incorporated by reference
−Removed: to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
−Removed: Rights Agreement, dated September 24, 2021, by and among the Company and the parties signatory thereto (incorporated by reference
−Removed: to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
−Removed: Guarantee, dated September 24, 2021, by and among the Company and the purchasers signatory thereto (incorporated by reference to
−Removed: Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
−Removed: Agreement, dated September 24, 2021, by and among the Company, EBI OpCo, Inc., Covistat, Inc.
−Removed: and the other parties signatory thereto
−Removed: (incorporated by reference to Exhibit 10.4 filed with the registrant’s Current Report on Form 8-K initially filed on September
+Added: Manufacturing Agreement between Recro Gaineville LLC and the Company dated September 11, 2019 (incorporated by reference to Exhibit 10.35 filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
+Added: Form of Exchange Agreement between Leisure Acquisition Corp.
+Added: and the holders of Private Placement Warrants (incorporated by reference to Exhibit 10.36(a) filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
+Added: Form of Exchange Agreement to be entered into by the Company with each of the Sponsors and the Strategic Investor (incorporated by reference to Exhibit 10.36(b) filed with the registrant’s Registration Statement on Form S-4 (File No.333-254279) initially filed on March 15, 2021)
+Added: Securities Purchase Agreement, dated September 24, 2021 by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
+Added: Registration Rights Agreement, dated September 24, 2021, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
+Added: Subsidiary Guarantee, dated September 24, 2021, by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
Security Agreement, dated September 24, 2021, by and among the Company, EBI OpCo, Inc., Covistat, Inc.
−Removed: and the other parties signatory
−Removed: thereto (incorporated by reference to Exhibit 10.5 filed with the registrant’s Current Report on Form 8-K initially filed on
−Removed: September 27, 2021)
−Removed: Agreement, dated December 27, 2021, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit
−Removed: 10.6 filed with the registrant’s Current Report on Form 8-K initially filed on December 27, 2021)
−Removed: Letter Agreement, dated January 16, 2022, by and among the Company and the parties signatory thereto (incorporated by reference to
−Removed: Exhibit 10.7 filed with the registrant’s Current Report on Form 8-K initially filed on January 18, 2022)
−Removed: Purchase Agreement, dated June 30, 2022, by and among the Company and the purchasers signatory thereto (incorporated by reference
−Removed: to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
−Removed: Rights Agreement, dated June 30, 2022, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit
−Removed: 10.2 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
−Removed: Guarantee, dated June 30, 2022, by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit
−Removed: 10.3 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
−Removed: Agreement, dated June 30, 2022, by and among the Company, EBI OpCo, Inc., Covistat, Inc.
−Removed: and the other parties signatory thereto
−Removed: (incorporated by reference to Exhibit 10.4 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
+Added: and the other parties signatory thereto (incorporated by reference to Exhibit 10.4 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
+Added: Patent Security Agreement, dated September 24, 2021, by and among the Company, EBI OpCo, Inc., Covistat, Inc.
+Added: and the other parties signatory thereto (incorporated by reference to Exhibit 10.5 filed with the registrant’s Current Report on Form 8-K initially filed on September 27, 2021)
+Added: Securities Purchase Agreement, dated June 30, 2022, by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
+Added: Registration Rights Agreement, dated June 30, 2022, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
+Added: Subsidiary Guarantee, dated June 30, 2022, by and among the Company and the purchasers signatory thereto (incorporated by reference to Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
Security Agreement, dated June 30, 2022, by and among the Company, EBI OpCo, Inc., Covistat, Inc.
−Removed: and the other parties signatory
−Removed: thereto (incorporated by reference to Exhibit 10.5 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
−Removed: Agreement, dated January 12, 2023, by and among the Company and the parties signatory thereto (incorporated by reference to Exhibit
−Removed: 10.6 filed with the registrant’s Current Report on Form 8-K on January 13, 2023)
−Removed: 2023 Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 filed with the registrant’s Current Report on
−Removed: Form 8-K (File No.
+Added: and the other parties signatory thereto (incorporated by reference to Exhibit 10.4 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
+Added: Patent Security Agreement, dated June 30, 2022, by and among the Company, EBI OpCo, Inc., Covistat, Inc.
+Added: and the other parties signatory thereto (incorporated by reference to Exhibit 10.5 filed with the registrant’s Current Report on Form 8-K on July 6, 2022)
+Added: October 2023 Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on October 24, 2023)
−Removed: of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form
−Removed: 8-K (File No.
+Added: Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on October 24, 2023)
−Removed: of Subsidiary Guaranty (incorporated by reference to Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K (File
+Added: Form of Subsidiary Guaranty (incorporated by reference to Exhibit 10.3 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on October 24, 2023)
−Removed: of Security Agreement (incorporated by reference to Exhibit 10.4 filed with the registrant’s Current Report on Form 8-K (File
+Added: Form of Security Agreement (incorporated by reference to Exhibit 10.4 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on October 24, 2023)
−Removed: of Patent Security Agreement (incorporated by reference to Exhibit 10.5 filed with the registrant’s Current Report on Form
−Removed: 8-K (File No.
+Added: Form of Patent Security Agreement (incorporated by reference to Exhibit 10.5 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on October 24, 2023)
−Removed: of Inducement Letter Agreement, dated as of February 12, 2024 (incorporated by reference to Exhibit 10.1 filed with the registrant’s
−Removed: Current Report on Form 8-K (File No.
−Removed: 001-38306) on February 14, 2024)
−Removed: of Waiver, dated February 12, 2024, under the Securities Purchase Agreement dated October 23, 2023 ((incorporated by reference to
−Removed: Exhibit 10.2 filed with the registrant’s Current Report on Form 8-K (File No.
−Removed: 001-38306) on February 14, 2024)
−Removed: Development and Commercial Manufacturing Supply Master Services Agreement with Galephar Pharmaceutical Research, Inc.
−Removed: (incorporated
−Removed: by reference to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K (File No.
+Added: Product Development and Commercial Manufacturing Supply Master Services Agreement with Galephar Pharmaceutical Research, Inc.
+Added: (incorporated by reference to Exhibit 10.1 filed with the registrant’s Current Report on Form 8-K (File No.
001-38306) on February 4, 2025)
−Removed: Code of Business Conduct (incorporated by reference to Exhibit 14 filed with the registrant’s Annual Report on Form 10-K (File
+Added: Company’s Code of Business Conduct (incorporated by reference to Exhibit 14 filed with the registrant’s Annual Report on Form 10-K (File No.
001-38306) on March 30, 2023)
−Removed: of Subsidiaries (incorporated by reference to Exhibit 21 filed with the Registration Statement on Form S-1 (333-268038) filed on
−Removed: October 28, 2022)
−Removed: Consent of Moss Adams LLP, Independent Registered Public Accounting Firm
+Added: Company’s Insider Trading Policy
+Added: List of Subsidiaries (incorporated by reference to Exhibit 21 filed with the Registration Statement on Form S-1 (333-268038) filed on October 28, 2022)
+Added: Consent of Baker Tilly US, LLP, Independent Registered Public Accounting Firm
Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
4 unchanged sentences
Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: relating to recovery of erroneously awarded compensation (incorporated by reference to Exhibit 97 filed with the registrant’s
−Removed: Annual Report on Form 10-K (File No.
+Added: Policy relating to recovery of erroneously awarded compensation (incorporated by reference to Exhibit 97 filed with the registrant’s Annual Report on Form 10-K (File No.
001-38306) on March 15, 2024)
23 unchanged sentences
Financial and Accounting Officer)
−Removed: Andrew Benton
William Chang
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.